Hypocholesterolemic effect of hesperetin mediated by inhibition of 3-hydroxy-3-methylgultaryl coenzyme a reductase and acyl coenzyme A: Cholesterol acyltransferase in rats fed high-cholesterol diet

被引:39
作者
Lee, SH
Jeong, TS
Park, YB
Kwon, YK
Choi, MS
Bok, SH
机构
[1] Korea Res Inst Biosci & Biotechnol, KIST, Taejon 305600, South Korea
[2] Kyungpook Natl Univ, Dept Food Sci & Nutr, Taegu 702701, South Korea
[3] Kyungpook Natl Univ, Dept Genet Engn, Taegu 702701, South Korea
关键词
high-cholesterol diet; hesperetin; HMG-CoA reductase; ACAT; fecal neutral sterols;
D O I
10.1016/S0271-5317(99)00085-8
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
HMG-CoA reductase and ACAT are associated with regulation of cholesterol metabolism. In present study, the deglycosylated form of hesperidin, hesperetin, was tested both in vivo and in vitro to examine potential differences in mechanism through which hesperetin might affect cholesterol metabolism. When tested in vitro, hesperetin had no inhibitory effect on either HMG-CoA reductase or ACAT. Male rats were fed a high-cholesterol (1%, w/w) diet with or without hesperetin for 42 d to determine hesperetin effects on plasma lipid levels and hepatic cholesterol metabolism. Hesperetin did not change the levels of hepatic lipids, but decreased the concentration of plasma cholesterol (3.24 mmol/L vs. 3.80 mmol/L). Plasma triglyceride level was not different between control and hesperetin-supplemented group (1.12 mol/L vs. 1.29 mmol/L). HMG-CoA reductase and ACAT activities in the liver were significantly reduced by hesperetin supplementation (2005.0 pmole.min(-1) mg proteim(-1) vs. 2487.2 pmole.min(-1) mg protein' for HMG-CoA reductase, 616.4 pmole.min(-1) mg proteim(-1) vs. 806.2 pmoles/min per mg for ACAT). The most noticeble change by the hesperetin supplementation was a marked decrease in daily excretion of fecal neutral sterols (178.7 mg/d vs. 521.9 mg/d). Results indicate that hesperetin decreased the plasma cholesterol level in rats fed a high-cholesterol diet. (C) 1999 Elsevier Science Inc.
引用
收藏
页码:1245 / 1258
页数:14
相关论文
共 51 条
[1]  
Aboobaker V S, 1994, In Vivo, V8, P1095
[2]   MEVINOLIN - A HIGHLY POTENT COMPETITIVE INHIBITOR OF HYDROXYMETHYLGLUTARYL-COENZYME-A REDUCTASE AND A CHOLESTEROL-LOWERING AGENT [J].
ALBERTS, AW ;
CHEN, J ;
KURON, G ;
HUNT, V ;
HUFF, J ;
HOFFMAN, C ;
ROTHROCK, J ;
LOPEZ, M ;
JOSHUA, H ;
HARRIS, E ;
PATCHETT, A ;
MONAGHAN, R ;
CURRIE, S ;
STAPLEY, E ;
ALBERSSCHONBERG, G ;
HENSENS, O ;
HIRSHFIELD, J ;
HOOGSTEEN, K ;
LIESCH, J ;
SPRINGER, J .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1980, 77 (07) :3957-3961
[3]   DISCOVERY, BIOCHEMISTRY AND BIOLOGY OF LOVASTATIN [J].
ALBERTS, AW .
AMERICAN JOURNAL OF CARDIOLOGY, 1988, 62 (15) :J10-J15
[4]  
ALLAIN CC, 1974, CLIN CHEM, V20, P470
[5]   Flavanone absorption after naringin, hesperidin, and citrus administration [J].
Ameer, B ;
Weintraub, RA ;
Johnson, JV ;
Yost, RA ;
Rouseff, RL .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 60 (01) :34-40
[6]   RG-12561 (DALVASTATIN) - A NOVEL SYNTHETIC INHIBITOR OF HMG-COA REDUCTASE AND CHOLESTEROL-LOWERING AGENT [J].
AMIN, D ;
GUSTAFSON, SK ;
WEINACHT, JM ;
CORNELL, SA ;
NEUENSCHWANDER, K ;
KOSMIDER, B ;
SCOTESE, AC ;
REGAN, JR ;
PERRONE, MH .
PHARMACOLOGY, 1993, 46 (01) :13-22
[7]  
[Anonymous], J NUTR
[8]  
BASARKAR PW, 1981, INDIAN J EXP BIOL, V19, P787
[9]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[10]  
BROWN MS, 1980, J BIOL CHEM, V255, P9344